Antares Pharma Stock Price, News & Analysis (NASDAQ:ATRS)

$2.23 +0.02 (+0.90 %)
(As of 02/22/2018 04:18 AM ET)
Previous Close$2.23
Today's Range$2.18 - $2.27
52-Week Range$1.58 - $4.09
Volume1.15 million shs
Average Volume1.32 million shs
Market Capitalization$348.79 million
P/E Ratio-20.27
Dividend YieldN/A
Beta0.3

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorHealthcare
SymbolNASDAQ:ATRS
CUSIP03664210
Phone+1-609-3593020

Debt

Debt-to-Equity Ratio0.69%
Current Ratio3.34%
Quick Ratio2.89%

Price-To-Earnings

Trailing P/E Ratio-20.2727272727273
Forward P/E Ratio-20.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.22 million
Price / Sales6.69
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book7.69

Profitability

Trailing EPS($0.11)
Net Income$-24,330,000.00
Net Margins-32.06%
Return on Equity-43.05%
Return on Assets-24.14%

Miscellaneous

Employees110
Outstanding Shares156,670,000

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, November, 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The specialty pharmaceutical company had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.01 million. Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. View Antares Pharma's Earnings History.

Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2018?

4 equities research analysts have issued 12 month price targets for Antares Pharma's shares. Their predictions range from $3.00 to $5.00. On average, they expect Antares Pharma's stock price to reach $4.08 in the next twelve months. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:

  • Leonard S. Jacob M.D., Ph.D., Independent Chairman of the Board (Age 68)
  • Robert F. Apple CPA, President, Chief Executive Officer, Director (Age 51)
  • Fred M. Powell CPA, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer (Age 56)
  • Peter J. Graham, Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer (Age 50)
  • Thomas J. Garrity, Independent Director (Age 68)
  • Jacques Gonella Ph.D., Independent Director (Age 75)
  • Anton G. Gueth, Independent Director (Age 60)
  • Robert P. Roche Jr., Independent Director (Age 61)
  • Marvin S. Samson, Independent Director (Age 75)

Who owns Antares Pharma stock?

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.96%), Armistice Capital LLC (4.85%), Broadfin Capital LLC (2.90%), Perceptive Advisors LLC (2.39%), JW Asset Management LLC (1.20%) and Wells Fargo & Company MN (1.02%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Who sold Antares Pharma stock? Who is selling Antares Pharma stock?

Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Perceptive Advisors LLC, Deutsche Bank AG, Goldman Sachs Group Inc., Fuller & Thaler Asset Management Inc., California Public Employees Retirement System, Perkins Capital Management Inc. and Avenir Corp. Company insiders that have sold Antares Pharma company stock in the last year include Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Who bought Antares Pharma stock? Who is buying Antares Pharma stock?

Antares Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Broadfin Capital LLC, TIAA FSB, Wells Fargo & Company MN, Guggenheim Capital LLC, JW Asset Management LLC, Advisor Group Inc. and BlackRock Inc.. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham and Robert F Apple. View Insider Buying and Selling for Antares Pharma.

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of Antares Pharma stock can currently be purchased for approximately $2.23.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $348.79 million and generates $52.22 million in revenue each year. The specialty pharmaceutical company earns $-24,330,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 110 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is SUITE 300, 100 PRINCETON SOUTH, EWING, NJ 8628, United States. The specialty pharmaceutical company can be reached via phone at +1-609-3593020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (ATRS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Antares Pharma (NASDAQ:ATRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.253.25
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $4.08$3.95$3.95$4.58
Price Target Upside: 105.81% upside138.67% upside138.67% upside45.70% upside

Antares Pharma (NASDAQ:ATRS) Consensus Price Target History

Price Target History for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018HC WainwrightReiterated RatingBuy$4.00LowView Rating Details
10/23/2017Piper Jaffray CompaniesSet Price TargetBuy$3.00N/AView Rating Details
6/23/2017Chardan CapitalInitiated CoverageBuy$5.00HighView Rating Details
4/20/2017Raymond James FinancialInitiated CoverageStrong-Buy$4.30LowView Rating Details
5/10/2016Jefferies GroupReiterated RatingBuy$3.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Antares Pharma (NASDAQ:ATRS) Earnings History and Estimates Chart

Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.03)($0.03)$14.01 million$15.10 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.03)($0.02)$12.99 million$13.42 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.01)($0.01)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.01)($0.02)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.02)($0.02)ViewN/AView Earnings Details
3/14/2011Q4 2010($0.02)($0.02)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.02)($0.02)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.04)($0.02)ViewN/AView Earnings Details
3/23/2010Q4 2009($0.03)($0.03)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.03)($0.04)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.06)($0.03)ViewN/AView Earnings Details
5/13/2009Q1 2009($0.06)($0.04)ViewN/AView Earnings Details
3/25/2009Q4 2008($0.05)($0.04)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.06)($0.05)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.05)($0.05)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.04)($0.05)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.03)($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Antares Pharma (NASDAQ:ATRS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.11 EPS
Next Year EPS Consensus Estimate: $0.01 EPS

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 34.20%
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/9/2017Leonard S JacobDirectorSell230,000$4.05$931,500.00View SEC Filing  
10/3/2017Thomas J GarrityDirectorSell30,000$3.50$105,000.00View SEC Filing  
6/9/2017Fred M PowellInsiderBuy130,000$2.79$362,700.00331,434View SEC Filing  
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00927,002View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18238,885View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00927,002View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00238,885View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00190,213View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00100,000View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.0020,000View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00270,216View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00218,885View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00517,164View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.0038,172View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00708,734View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00368,918View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00245,976View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00708,734View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Antares Pharma (NASDAQ ATRS) News Headlines

Source:
DateHeadline
-$0.03 EPS Expected for Antares Pharma Inc (ATRS) This Quarter-$0.03 EPS Expected for Antares Pharma Inc (ATRS) This Quarter
www.americanbankingnews.com - February 21 at 2:32 PM
Analyzing Antares Pharma (ATRS) and Given Imaging (GIVN)Analyzing Antares Pharma (ATRS) and Given Imaging (GIVN)
www.americanbankingnews.com - February 19 at 12:16 PM
Critical Contrast: DexCom (DXCM) and Antares Pharma (ATRS)Critical Contrast: DexCom (DXCM) and Antares Pharma (ATRS)
www.americanbankingnews.com - February 15 at 11:12 PM
Antares Pharma (ATRS) Reports FDA Approval of Partners Product Utilizing Our QuickShot Auto InjectorAntares Pharma (ATRS) Reports FDA Approval of Partner's Product Utilizing Our QuickShot Auto Injector
www.streetinsider.com - February 15 at 5:24 PM
Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring TodayWhy AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today
finance.yahoo.com - February 15 at 5:24 PM
Antares Pharmas (ATRS) Buy Rating Reaffirmed at HC WainwrightAntares Pharma's (ATRS) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - February 15 at 9:58 AM
Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of Influence
finance.yahoo.com - February 15 at 9:16 AM
Antares Pharma Inc (ATRS) Expected to Post Quarterly Sales of $14.80 MillionAntares Pharma Inc (ATRS) Expected to Post Quarterly Sales of $14.80 Million
www.americanbankingnews.com - February 6 at 11:28 AM
Antares Pharma Inc (ATRS) Given Consensus Recommendation of "Buy" by BrokeragesAntares Pharma Inc (ATRS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 6 at 1:18 AM
 Analysts Expect Antares Pharma Inc (ATRS) to Announce -$0.03 Earnings Per Share Analysts Expect Antares Pharma Inc (ATRS) to Announce -$0.03 Earnings Per Share
www.americanbankingnews.com - February 4 at 1:20 PM
Antares Pharma (ATRS) versus Orthofix International (OFIX) Critical ComparisonAntares Pharma (ATRS) versus Orthofix International (OFIX) Critical Comparison
www.americanbankingnews.com - January 27 at 3:32 AM
Financial Comparison: Antares Pharma (ATRS) and Cytori Therapeutics (CYTX)Financial Comparison: Antares Pharma (ATRS) and Cytori Therapeutics (CYTX)
www.americanbankingnews.com - January 24 at 5:42 PM
Zacks: Brokerages Expect Antares Pharma, Inc. (ATRS) to Announce -$0.03 Earnings Per ShareZacks: Brokerages Expect Antares Pharma, Inc. (ATRS) to Announce -$0.03 Earnings Per Share
www.americanbankingnews.com - January 18 at 3:30 PM
Antares Pharma, Inc. (ATRS) Given Consensus Recommendation of "Buy" by AnalystsAntares Pharma, Inc. (ATRS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 12 at 1:50 AM
Antares Pharma, Inc. (ATRS) Expected to Announce Quarterly Sales of $14.80 MillionAntares Pharma, Inc. (ATRS) Expected to Announce Quarterly Sales of $14.80 Million
www.americanbankingnews.com - January 3 at 2:36 AM
Antares Pharma, Inc. (ATRS) Expected to Post Earnings of -$0.03 Per ShareAntares Pharma, Inc. (ATRS) Expected to Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - January 1 at 9:10 PM
Antares Pharma (ATRS) Rating Increased to Buy at BidaskClubAntares Pharma (ATRS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - December 23 at 2:56 PM
Antares Pharma (ATRS) Reports Written Request for Type A Meeting Submitted to FDA in Response to CRL received Regarding NDA for XYOSTEDAntares Pharma (ATRS) Reports Written Request for Type A Meeting Submitted to FDA in Response to CRL received Regarding NDA for XYOSTED
www.streetinsider.com - December 22 at 3:49 PM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline - December 22, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline - December 22, 2017
finance.yahoo.com - December 22 at 3:49 PM
ATRS Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the ... - Business Wire (press release)ATRS Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the ... - Business Wire (press release)
www.businesswire.com - December 22 at 8:44 AM
Antares Pharma Provides XYOSTED™ Regulatory Update Nasdaq ... - GlobeNewswire (press release)Antares Pharma Provides XYOSTED™ Regulatory Update Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - December 22 at 8:44 AM
ATRS UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - December 20 at 8:31 AM
Glancy Prongay & Murray Reminds Investors of the December 22, 2017 Deadline in the Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)Glancy Prongay & Murray Reminds Investors of the December 22, 2017 Deadline in the Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)
finance.yahoo.com - December 20 at 8:31 AM
New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"
finance.yahoo.com - December 20 at 8:31 AM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm Before December 22ndBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm Before December 22nd
finance.yahoo.com - December 19 at 8:59 AM
$14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter$14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - December 18 at 10:16 PM
DEADLINE APPROACHING: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)DEADLINE APPROACHING: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - December 18 at 3:26 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline - December 22, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline - December 22, 2017
finance.yahoo.com - December 18 at 3:26 PM
FINAL DEADLINE ALERT:  Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The FirmFINAL DEADLINE ALERT:  Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The Firm
finance.yahoo.com - December 18 at 3:26 PM
Antares Pharma, Inc. (ATRS) Given Consensus Rating of "Buy" by AnalystsAntares Pharma, Inc. (ATRS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 18 at 1:54 AM
Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Antares ...Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Antares ...
www.prnewswire.com - December 15 at 8:37 AM
IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE RAPIDLY APPROACHING: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed on behalf of investors who purchased Antares Pharma, Inc.IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE RAPIDLY APPROACHING: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed on behalf of investors who purchased Antares Pharma, Inc.
finance.yahoo.com - December 14 at 8:54 AM
ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - December 14 at 8:54 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Antares Pharma, Inc. Shareholders of Commencement of a Class Action and a Lead Plaintiff Deadline of December 22, 2017 - ATRSEQUITY ALERT: Levi & Korsinsky, LLP Reminds Antares Pharma, Inc. Shareholders of Commencement of a Class Action and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 13 at 3:27 PM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm
finance.yahoo.com - December 13 at 8:49 AM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - December 13 at 8:49 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 9 at 9:01 AM
ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017ATRS EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Antares Pharma, Inc. and a Lead Plaintiff Deadline of December 22, 2017
finance.yahoo.com - December 7 at 8:49 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline: December 22, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) and Lead Plaintiff Deadline: December 22, 2017
finance.yahoo.com - December 6 at 3:26 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 6 at 9:11 AM
Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd Lead Plaintiff Deadline in Securities Class Action Against Antares Pharma, Inc. (ATRS)Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd Lead Plaintiff Deadline in Securities Class Action Against Antares Pharma, Inc. (ATRS)
finance.yahoo.com - December 5 at 3:26 PM
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Antares Pharma, Inc. Shareholders and a Lead Plaintiff Deadline of December 22, 2017 (ATRS)
finance.yahoo.com - December 5 at 3:26 PM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to ...ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to ...
www.businesswire.com - December 5 at 8:50 AM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to Contact the FirmATRS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Antares Pharma, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - December 5 at 8:50 AM
DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The Firm
finance.yahoo.com - December 1 at 11:21 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRSEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS
finance.yahoo.com - December 1 at 11:21 AM
Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - December 1 at 11:21 AM
ETFs with exposure to Antares Pharma, Inc. : November 30, 2017ETFs with exposure to Antares Pharma, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:26 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline: December 22, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline: December 22, 2017
finance.yahoo.com - November 29 at 3:25 PM
ATRS INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Antares Pharma, Inc. InvestorsATRS INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Antares Pharma, Inc. Investors
finance.yahoo.com - November 29 at 3:25 PM

SEC Filings

Antares Pharma (NASDAQ:ATRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Antares Pharma (NASDAQ ATRS) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.